Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

API Manufacturing: SOP for Out-of-Specification (OOS) Handling Procedure – V 2.0

Posted on By

API Manufacturing: SOP for Out-of-Specification (OOS) Handling Procedure – V 2.0

Standard Operating Procedure for Out-of-Specification (OOS) Handling in API Manufacturing

Department API Manufacturing
SOP No. SOP/API/134/2025
Supersedes SOP/API/134/2022
Page No. Page 1 of 9
Issue Date 13/04/2025
Effective Date 15/04/2025
Review Date 13/04/2026

1. Purpose

To establish a systematic procedure for handling Out-of-Specification (OOS) results generated during testing of raw materials, intermediates, and final Active Pharmaceutical Ingredients (APIs), ensuring thorough investigation, documentation, and compliance with applicable regulations.

2. Scope

This SOP applies to all Quality Control (QC) personnel, analysts, reviewers, and QA officers involved in handling and investigating test results that fall outside approved specification limits

during any phase of testing at the API manufacturing facility.

3. Responsibilities

  • QC Analyst: Identify and report OOS results immediately and initiate documentation.
  • QC Reviewer: Confirm the validity of the result and initiate investigation if required.
  • QA Officer: Participate in investigation, approve corrective/preventive actions, and close the OOS record.
  • Department Head (QC/QA): Review the investigation, assess impact, and approve final disposition.
See also  API Manufacturing: SOP for Monitoring of Crystallization End-Point - V 2.0

4. Accountability

The Head – Quality Assurance is accountable for ensuring timely and compliant investigation and resolution of all OOS events in accordance with regulatory expectations and internal SOPs.

5. Procedure

5.1 Identification of OOS

  1. An OOS result is defined as any test result that falls outside the approved specification or acceptance criteria.
  2. OOS results may arise during testing of:
    • Raw materials
    • In-process materials
    • Finished APIs
    • Stability samples
  3. Analyst must immediately inform the QC supervisor and record the result in the OOS Notification Form (Annexure-1).

5.2 Phase I: Laboratory Investigation

  1. Review the analytical method, calculation, raw data, instrument logs, reagents, and analyst’s technique.
  2. Perform a system suitability check.
  3. If no obvious errors are found, repeat the test using the same sample preparation (if stable).
  4. If the repeat result is within limits and there is an assignable error, document and conclude.
  5. If the repeat result is still OOS or the cause is not found, proceed to Phase II.

5.3 Phase II: Full-Scale Investigation

  1. QA initiates a formal investigation using OOS Investigation Form (Annexure-2).
  2. Investigate:
    • Manufacturing process deviations
    • Sample mix-up or contamination
    • Storage conditions
    • Previous batch trends and history
  3. Interview involved personnel and document findings.
  4. Define root cause and propose CAPA (Corrective and Preventive Action).
  5. QA reviews and approves the investigation report.
See also  API Manufacturing: SOP for Cross-Verification of IPC Data by QA - V 2.0

5.4 Re-sampling and Re-testing Criteria

  1. Re-sampling is allowed only if there is evidence of sample compromise or handling error.
  2. Re-testing is permitted under QA-approved protocol with documented justification.
  3. Original OOS result cannot be disregarded unless invalidated with scientifically sound reason.

5.5 Final Disposition

  1. Based on investigation outcome, QA recommends:
    • Batch rejection
    • Reprocessing or re-testing
    • Product recall or reporting to regulatory authorities (if applicable)
  2. Final decision is documented in the OOS Final Disposition Log (Annexure-3).

5.6 Trending and Review

  1. QA shall review all closed OOS records quarterly to identify recurring issues.
  2. Prepare trend reports and present during management review meetings.

6. Abbreviations

  • OOS: Out of Specification
  • CAPA: Corrective and Preventive Action
  • QA: Quality Assurance
  • QC: Quality Control
  • SOP: Standard Operating Procedure

7. Documents

  1. OOS Notification Form (Annexure-1)
  2. OOS Investigation Form (Annexure-2)
  3. OOS Final Disposition Log (Annexure-3)
  4. CAPA Register
See also  API Manufacturing: SOP for Online Monitoring using PAT Tools - V 2.0

8. References

  • US FDA Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results
  • ICH Q7 – GMP for APIs
  • 21 CFR Part 211
  • MHRA GxP Data Integrity Guidance

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: OOS Notification Form

Date Sample ID Test Result Limit Analyst Supervisor Signature
13/04/2025 API-20250413 Assay 91.2% 95–105% Sunita Reddy Rajesh Kumar

Annexure-2: OOS Investigation Form

Investigation No. OOS/025/2025
Details of Deviation Assay below limit
Root Cause Weighing error during sample prep
CAPA Proposed Retraining of analysts, balance calibration check
QA Review Comments Adequate and accepted

Annexure-3: OOS Final Disposition Log

Date Sample ID Result Disposition QA Sign
15/04/2025 API-20250413 OOS Confirmed Batch Rejected QA Head

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP Regulatory Compliance QA Head
13/04/2025 2.0 Added trending and disposition log Internal Audit Observation QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: Creams: SOP for Conducting Endotoxin Testing for Cream Products – V 2.0
Next Post: Elixir Department: SOP for Equipment Verification Before Use – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version